Menu

Recent Interviews

Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)

info@saturnoil.com

+1-587-392-7900

Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"


15. September 2021 | 12:17 CET

Valneva, Cardiol Therapeutics, Sartorius: Healthy returns in every market phase

  • Biotechnology
Photo credits: pixabay.com

The pandemic has given the healthcare sector a boost. If people were still somewhat hesitant to talk about the digitization of the healthcare system in 2019, the epidemic has clearly revealed where the weaknesses are. New drugs and procedures could also be tested under the new framework conditions. If nothing else, the industry is getting renewed attention as a result. We outline three companies and explain whether the shares have prospects or not.

time to read: 3 minutes by Nico Popp
ISIN: VALNEVA SE EO -_15 | FR0004056851 , CARDIOL THERAPEUTICS | CA14161Y2006 , SARTORIUS AG O.N. | DE0007165607


 

Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author


Valneva: Here is what happens after the crash

The Valneva share has caused a stir on the trading floor in recent weeks. The French Company is working on a classic inactivated vaccine against Sars-Cov2. This new vaccine could be an opportunity, especially given the remaining 25% or so of the German population who have been unable to get the shot. The assumption is that the willingness to vaccinate could increase with Valneva's vaccine. Many people are skeptical of mRNA technology, which is the basis for vaccines from BioNTech and Moderna. But the vaccine hopes surrounding Valneva have been dampened - the UK withdrew its order.

While the approval process is expected to continue, the hopes of many shareholders have been dashed. As recently as last Friday, the share was trading around EUR 20 - and has crashed to around EUR 12.50 at present. As the order from the UK was the only major order, the situation for Valneva is serious. With such an order behind it, it is much easier to swiftly implement all the necessary investments as part of an approval process. Since analysts have also become more skeptical after the cancellation of the large order, investors should continue to be cautious about Valneva.

Cardiol Therapeutics: Nasdaq investors are taking notice

One company that has benefited from the Corona pandemic is Cardiol Therapeutics. The biotech Company addresses inflammatory heart disease and is in a Phase II trial with its compound CardiolRx. The Company recently received the green light from the US Food and Drug Administration (FDA). The main focus is on the safety of the active ingredient and also the positive effects on patients with acute myocarditis, i.e. inflammation of the heart muscle.

The latter condition can occur in connection with Covid-19 but also as an extremely rare vaccination reaction. As a rule, such inflammations heal without consequences. However, patients with pre-existing conditions, obesity or permanent stress may suffer subsequent damage, and this is where Cardiol Therapeutics comes in. Cardiovascular diseases are one of the most frequent causes of death in Western countries. Cardiol's active ingredients can be regarded as safe and effective with a high degree of probability according to the current state of scientific knowledge, making the shares of Cardiol Therapeutics appear attractive. Since the stock is now listed on the Nasdaq and can attract the attention of the most important biotech investors there, speculative investors should take a closer look at the share. Currently, the value is correcting after a spectacular rise.

Sartorius: Hidden Champion in several areas

The Sartorius share has also experienced a spectacular rise, with the share climbing like clockwork for years. Sartorius makes disposables for drug manufacturing, laboratory instruments and other consumables. In 2020, sales of the relatively conservative Company rose a whopping 27.8%. However, since order intake grew even more dynamically simultaneously, investors need not be alarmed at all about the 2021 figures. Sartorius is benefiting from the pandemic but also from progress in the healthcare system in general. Since Sartorius is active not only in Europe (40% share of sales) but also in the Americas (approx. 34%) and Asia-Pacific (approx. 25%), the Goettingen-based Company is a true hidden champion. On top of that, there is a slim dividend.


Although investors are unlikely to make any more big leaps with Sartorius shares, the stock could become attractive after a correction. Despite the correction, Valneva remains rather uninteresting - the withdrawal of its only customer is unsettling. On the other hand, everything is going according to plan at Cardiol Therapeutics. Here, a promising active ingredient finally seems to be getting the attention it deserves. The share is worth a look, especially during the correction.


Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

14. September 2021 | 13:10 CET | by Nico Popp

BioNTech, Defence Therapeutics, Valneva: Here, the overall market (almost) does not matter

  • Biotechnology

Is the crash coming or not? Meanwhile, even Wall Street banks are warning of an imminent crash event. Many commentators are jumping on the bandwagon. The reasons: Delta variation, supply problems and inflation, and an economy that could suffer. But if you compare the crashes of the past years, one thing becomes clear: Only the fewest price setbacks came with notice! We present three stocks that many investors believe can combine growth and security.

Read

10. September 2021 | 12:43 CET | by André Will-Laudien

NanoRepro, XPhyto Therapeutics, BioNTech, Valneva - The next biotech wave is rolling!

  • Biotechnology

So far, vaccine manufacturers can maintain their high valuation because the next wave of new infections is rolling in. In Germany, tests will be subject to fees starting in October, making public life more expensive for those who want to participate. In surveys, most German citizens have expressed support for fee-based testing; probably, the populations here should be separated into "vaccinated" and "unvaccinated" to indicate general opinion accurately. Four interesting values benefit from the current situation.

Read

03. September 2021 | 13:27 CET | by Stefan Feulner

MorphoSys, Defence Therapeutics, CureVac, BioNTech - Dramatic need

  • Biotechnology

While in Germany, 50.4 million citizens, or 60.7% of the population, are already fully vaccinated, and there is already discussion about booster vaccinations, the global average is just one in four. Thus, there is still an enormous demand for vaccines from various manufacturers. In addition to the French pharmaceutical Company Sanofi, a German vaccine producer could also celebrate a stock market comeback due to its second-generation vaccine.

Read